ReNeuron Group plc
("ReNeuron" or the "Company")
ReNeuron to present new data at the Extracellular Vesicle-Based Therapeutic Development Summit
Dr Randolph Corteling, Chief Scientific Officer invited as guest speaker
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosomes technologies, announces that the Company will be attending the Extracellular Vesicle-Based Therapeutic Development Summit from the 4-6 October in Boston, MA.
As part of the event, Dr Corteling will be presenting new data on ReNeuron's customisable Exosomes delivery platform in the morning session on 6 October, exploring the latest advancements of Extracellular Vesicle-Based ('EV') cargo delivery. Dr Corteling's presentation entitled Targeted Delivery of Therapeutic Payloads Using Engineered Stem Cell Exosome will commence at 10:00 EST.
The Extracellular Vesicle-Based Therapeutic Development Summit in Boston brings together international experts from across the industry focusing on accelerating the discovery, translation and large-scale manufacturing of Exosomes and EV's, through a series of abstracts, presentations, panel discussions and partnering/networking events. Further information on the event can be found here: https://ev-based-therapeutics.com/
The presentation will be made available after the event on the Company's website: https://www.reneuron.com/investors/presentations/
ENDS
Contacts:
|
ReNeuron |
|
|
Catherine Isted, Chief Executive Officer |
Via Walbrook PR |
|
John Hawkins, Chief Financial Officer |
|
|
|
|
|
Walbrook PR (Media & Investor Relations) |
+44 (0)20 7933 8780 or reneuron@walbrookpr.com |
|
Paul McManus / Alice Woodings |
+44 (0)7980 541 893 / +44 (0)7407 804 654 |
About ReNeuron
ReNeuron is a UK based Proprietary Stem Cell derived Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.
ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Company has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
The Company has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-licence both these programmes in other territories.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach†in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
